Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Targeted therapies

Good news for advanced-stage pancreatic neuroendocrine tumors

Nature Reviews Clinical Oncology volume 8, pages 258–259 (2011)Cite this article

Subjects

A phase III, randomized, placebo-controlled trial in 171 patients with advanced-stage pancreatic neuroendocrine tumors demonstrated a significant improvement in progression-free survival with sunitinib treatment. We discuss the results of this trial in the context of other studies that have assessed treatment of pancreatic neuroendocrine tumors.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Yao, J. C. et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 26, 3063–3072 (2008).

    Article  Google Scholar 

  2. McCollum, A. D. et al. Lack of efficacy of streptozotocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am. J. Clin. Oncol. 27, 485–488 (2004).

    Article  CAS  Google Scholar 

  3. Faivre, S., Demetri, G., Sargent, W. & Raymond, E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov. 6, 734–745 (2007).

    Article  CAS  Google Scholar 

  4. Kulke, M. H. et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 26, 3403–3410 (2008).

    Article  CAS  Google Scholar 

  5. Raymond, E. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501–513 (2011).

    Article  CAS  Google Scholar 

  6. Shen, H. C. et al. Recapitulation of pancreatic neuroendocrine tumors in human multiple endocrine neoplasia type I syndrome via Pdx1-directed inactivation of Men1. Cancer Res. 69, 1858–1866 (2009).

    Article  CAS  Google Scholar 

  7. Yao, J. C. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514–523 (2011).

    Article  CAS  Google Scholar 

  8. Alsamarai, S., Libutti, S. K. & Saif, M. W. Updates in pancreatic neuroendocrine carcinoma. Highlights from the “2010 ASCO Annual Meeting”. Chicago, IL, USA. June 4–8, 2010. JOP 11, 336–340 (2010).

    PubMed  Google Scholar 

  9. Jiao, Y. et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331, 1199–1203 (2011).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Albert Einstein College of Medicine, 1300 Morris Park Avenue, Belfer 312, Bronx, 10461, NY, USA

    Allen M. Spiegel

  2. Albert Einstein College of Medicine, 1300 Morris Park Avenue, Ullmann 9, Bronx, 10461, NY, USA

    Steven K. Libutti

Authors
  1. Allen M. Spiegel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven K. Libutti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Allen M. Spiegel.

Ethics declarations

Competing interests

S. K. Libutti has received a travel grant from Novartis. A. M. Spiegel declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Spiegel, A., Libutti, S. Good news for advanced-stage pancreatic neuroendocrine tumors. Nat Rev Clin Oncol 8, 258–259 (2011). https://doi.org/10.1038/nrclinonc.2011.50

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2011.50

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing